{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:40:33Z","timestamp":1792071633563,"version":"4.4.0"},"reference-count":145,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000070","name":"National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","award":["R01-EB022563"],"award-info":[{"award-number":["R01-EB022563"]}],"id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017065","name":"Rogel Cancer Center, University of Michigan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001794","name":"Pediatric Brain Tumor Foundation","doi-asserted-by":"publisher","award":["G023387"],"award-info":[{"award-number":["G023387"]}],"id":[{"id":"10.13039\/100001794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007270","name":"University of Michigan","doi-asserted-by":"publisher","award":["G023089"],"award-info":[{"award-number":["G023089"]}],"id":[{"id":"10.13039\/100007270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010612","name":"ChadTough Foundation","doi-asserted-by":"publisher","award":["G023419"],"award-info":[{"award-number":["G023419"]}],"id":[{"id":"10.13039\/100010612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R21-NS123879-01"],"award-info":[{"award-number":["R21-NS123879-01"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R37-NS094804"],"award-info":[{"award-number":["R37-NS094804"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01-NS122165"],"award-info":[{"award-number":["R01-NS122165"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01-NS122536"],"award-info":[{"award-number":["R01-NS122536"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01-NS105556"],"award-info":[{"award-number":["R01-NS105556"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01-NS124167"],"award-info":[{"award-number":["R01-NS124167"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01-NS076991"],"award-info":[{"award-number":["R01-NS076991"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01-NS122234"],"award-info":[{"award-number":["R01-NS122234"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01-NS127378"],"award-info":[{"award-number":["R01-NS127378"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01-NS082311"],"award-info":[{"award-number":["R01-NS082311"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01-NS096756"],"award-info":[{"award-number":["R01-NS096756"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01-CA243916"],"award-info":[{"award-number":["R01-CA243916"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.ymthe.2023.08.009","type":"journal-article","created":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T16:44:44Z","timestamp":1691858684000},"page":"2839-2860","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Combined cytotoxic and immune-stimulatory gene therapy using Ad-TK and Ad-Flt3L: Translational developments from rodents to glioma patients"],"prefix":"10.1016","volume":"31","author":[{"given":"Syed M.","family":"Faisal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria G.","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro R.","family":"Lowenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2023.08.009_bib1","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","article-title":"Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions","volume":"22","author":"Wen","year":"2020","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib2","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib3","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1158\/1078-0432.CCR-21-2750","article-title":"Glioblastoma clinical trials: Current landscape and opportunities for improvement","volume":"28","author":"Bagley","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2023.08.009_bib4","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41571-019-0177-5","article-title":"Challenges to curing primary brain tumours","volume":"16","author":"Aldape","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib5","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1038\/s41467-022-31262-y","article-title":"A phase I\/II study of triple-mutated oncolytic herpes virus G47\u0394 in patients with progressive glioblastoma","volume":"13","author":"Todo","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2023.08.009_bib6","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","article-title":"Intratumoral oncolytic herpes virus G47\u0394 for residual or recurrent glioblastoma: A phase 2 trial","volume":"28","author":"Todo","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2023.08.009_bib7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/14712598.2022.2157718","article-title":"Gene therapy for high grade glioma: The clinical experience","volume":"23","author":"Varela","year":"2023","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ymthe.2023.08.009_bib8","article-title":"Combined cytotoxic and immune therapy for primary adult high-grade glioma","author":"Umemura","year":"2022","journal-title":"medRxiv"},{"key":"10.1016\/j.ymthe.2023.08.009_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(23)00347-9","article-title":"Combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: a phase 1, first-in-human trial","author":"Umemura","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ymthe.2023.08.009_bib9","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJMoa1716435","article-title":"Recurrent glioblastoma treated with recombinant poliovirus","volume":"379","author":"Desjardins","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2023.08.009_bib10","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1200\/JCO.2011.35.5222","article-title":"Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma","volume":"29","author":"Chiocca","year":"2011","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib11","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/neuonc\/now002","article-title":"Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma","volume":"18","author":"Wheeler","year":"2016","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib12","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41593-021-00969-4","article-title":"AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset","volume":"25","author":"Goertsen","year":"2022","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ymthe.2023.08.009_bib13","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/s41551-022-00938-7","article-title":"Variants of the adeno-associated virus serotype 9 with enhanced penetration of the blood-brain barrier in rodents and primates","volume":"6","author":"Yao","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ymthe.2023.08.009_bib14","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2023.08.009_bib15","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib16","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11060-022-04083-8","article-title":"The trial effect in patients with glioblastoma: Effect of clinical trial enrollment on overall survival","volume":"159","author":"Melnick","year":"2022","journal-title":"J.\u00a0Neurooncol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib17","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1158\/1078-0432.CCR-09-3106","article-title":"Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States","volume":"16","author":"Grossman","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2023.08.009_bib18","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ymthe.2023.08.009_bib19","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/S1470-2045(17)30194-8","article-title":"European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/neuonc\/nos273","article-title":"Standards of care for treatment of recurrent glioblastoma--are we there yet?","volume":"15","author":"Weller","year":"2013","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib21","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2023.08.009_bib22","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11060-015-1802-5","article-title":"Systematic review and meta-analysis of phase I\/II targeted therapy combined with radiotherapy in patients with glioblastoma multiforme: Quality of report, toxicity, and survival","volume":"123","author":"dos Santos","year":"2015","journal-title":"J.\u00a0Neurooncol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1005069","article-title":"The complex interactions between the cellular and non-cellular components of the brain tumor microenvironmental landscape and their therapeutic implications","volume":"12","author":"Faisal","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib24","first-page":"vdaa013","article-title":"Suicide gene therapy for the treatment of high-grade glioma: past lessons, present trends, and future prospects","volume":"2","author":"Hossain","year":"2020","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.ymthe.2023.08.009_bib25","first-page":"1753","article-title":"Antineoplastic effects in rats of 5-fluorocytosine in combination with cytosine deaminase capsules","volume":"45","author":"Nishiyama","year":"1985","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2023.08.009_bib26","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/sj.mt.6300155","article-title":"Bystander killing of malignant glioma by bone marrow-derived tumor-infiltrating progenitor cells expressing a suicide gene","volume":"15","author":"Miletic","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2023.08.009_bib27","doi-asserted-by":"crossref","first-page":"6761","DOI":"10.1158\/1078-0432.CCR-07-1240","article-title":"Normal brain cells contribute to the bystander effect in suicide gene therapy of malignant glioma","volume":"13","author":"Miletic","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2023.08.009_bib28","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1159\/000091032","article-title":"Potent bystander effect in suicide gene therapy using neural stem cells transduced with herpes simplex virus thymidine kinase gene","volume":"69","author":"Li","year":"2005","journal-title":"Oncology"},{"key":"10.1016\/j.ymthe.2023.08.009_bib29","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1093\/neuonc\/noz060","article-title":"Long-term treatment with valganciclovir improves lentiviral suicide gene therapy of glioblastoma","volume":"21","author":"Hossain","year":"2019","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib31","doi-asserted-by":"crossref","first-page":"7194","DOI":"10.1158\/0008-5472.CAN-04-3434","article-title":"Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model","volume":"65","author":"Ali","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2023.08.009_bib32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/978-1-4939-8922-5_2","article-title":"Cancer suicide gene therapy with TK.007","volume":"1895","author":"Hossain","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib33","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/jnci\/82.4.297","article-title":"Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors","volume":"82","author":"Moolten","year":"1990","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.ymthe.2023.08.009_bib34","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1158\/1078-0432.CCR-09-0155","article-title":"Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity","volume":"15","author":"Candolfi","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2023.08.009_bib35","first-page":"1667","article-title":"A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons","volume":"241","author":"Geller","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2023.08.009_bib36","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/sj.gt.3301311","article-title":"Immune response induced by retrovirus-mediated HSV-tk\/GCV pharmacogene therapy in patients with glioblastoma multiforme","volume":"7","author":"Rainov","year":"2000","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2023.08.009_bib37","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1089\/104303400750038499","article-title":"A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme","volume":"11","author":"Rainov","year":"2000","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2023.08.009_bib38","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.it.2006.11.004","article-title":"What is immune privilege (not)?","volume":"28","author":"Galea","year":"2007","journal-title":"Trends Immunol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib39","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1471-4906(01)02063-4","article-title":"Immunology of viral-vector-mediated gene transfer into the brain: An evolutionary and developmental perspective","volume":"23","author":"Lowenstein","year":"2002","journal-title":"Trends Immunol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib40","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/08830185.2017.1357719","article-title":"CNS: Not an immunoprivilaged site anymore but a virtual secondary lymphoid organ","volume":"37","author":"Negi","year":"2018","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib41","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/ni.3666","article-title":"The movers and shapers in immune privilege of the CNS","volume":"18","author":"Engelhardt","year":"2017","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib42","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1172\/JCI90603","article-title":"Understanding the functions and relationships of the glymphatic system and meningeal lymphatics","volume":"127","author":"Louveau","year":"2017","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2023.08.009_bib43","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1084\/jem.20142290","article-title":"A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules","volume":"212","author":"Aspelund","year":"2015","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2023.08.009_bib44","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/s41593-018-0227-9","article-title":"CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature","volume":"21","author":"Louveau","year":"2018","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ymthe.2023.08.009_bib45","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature14432","article-title":"Structural and functional features of central nervous system lymphatic vessels","volume":"523","author":"Louveau","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2023.08.009_bib46","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2023.08.009_bib47","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMoa2209813","article-title":"Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma","volume":"387","author":"Gross","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2023.08.009_bib48","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2023.08.009_bib49","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.1200\/EDBK_323835","article-title":"Immune checkpoint inhibition in advanced bladder and kidney cancer: Responses and further management","volume":"41","author":"Parikh","year":"2021","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"10.1016\/j.ymthe.2023.08.009_bib50","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","article-title":"Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: A phase 3 prospective externally controlled cohort trial","volume":"9","author":"Liau","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib51","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: Current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ymthe.2023.08.009_bib52","article-title":"First-in-human trial of EphA2-redirected CAR T-cells in patients with recurrent glioblastoma: A preliminary report of three cases at the starting dose","volume":"11","author":"Lin","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib53","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","article-title":"CAR T\u00a0cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors","volume":"25","author":"Majzner","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2023.08.009_bib54","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41698-021-00233-9","article-title":"GD2 CAR T\u00a0cells against human glioblastoma","volume":"5","author":"Prapa","year":"2021","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib55","doi-asserted-by":"crossref","first-page":"8729","DOI":"10.1021\/acsnano.1c07492","article-title":"Systemic delivery of an adjuvant CXCR4-CXCL12 signaling inhibitor encapsulated in synthetic protein nanoparticles for glioma immunotherapy","volume":"16","author":"Alghamri","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.ymthe.2023.08.009_bib56","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1939601","article-title":"A novel miR1983-TLR7-IFNbeta circuit licenses NK cells to kill glioma cells, and is under the control of galectin-1","volume":"10","author":"Shah","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ymthe.2023.08.009_bib57","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/neuonc\/now009","article-title":"A phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma","volume":"18","author":"Brandes","year":"2016","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib58","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9230479","article-title":"Targeting mTOR in glioblastoma: Rationale and preclinical\/clinical evidence","volume":"2018","author":"Mecca","year":"2018","journal-title":"Dis. Markers"},{"key":"10.1016\/j.ymthe.2023.08.009_bib59","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/neuonc\/nox209","article-title":"A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: Results of NRG Oncology RTOG 0913","volume":"20","author":"Chinnaiyan","year":"2018","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib60","doi-asserted-by":"crossref","first-page":"5756","DOI":"10.1158\/1078-0432.CCR-13-3389","article-title":"Dual mTORC1\/2 blockade inhibits glioblastoma brain tumor initiating cells in\u00a0vitro and in\u00a0vivo and synergizes with temozolomide to increase orthotopic xenograft survival","volume":"20","author":"Luchman","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2023.08.009_bib61","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2023.08.009_bib62","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2019103790","article-title":"Microglia promote glioblastoma via mTOR-mediated immunosuppression of the tumour microenvironment","volume":"39","author":"Dumas","year":"2020","journal-title":"EMBO J."},{"key":"10.1016\/j.ymthe.2023.08.009_bib63","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1517\/14740338.2013.752814","article-title":"Adverse events associated with mTOR inhibitors","volume":"12","author":"Pallet","year":"2013","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.ymthe.2023.08.009_bib64","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/s41586-022-05213-y","article-title":"Brain-restricted mTOR inhibition with binary pharmacology","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2023.08.009_bib65","doi-asserted-by":"crossref","first-page":"6514","DOI":"10.1158\/1078-0432.CCR-21-1392","article-title":"Tumor cell IDO enhances immune suppression and decreases survival independent of tryptophan metabolism in glioblastoma","volume":"27","author":"Zhai","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2023.08.009_bib66","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): A phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib67","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.trecan.2020.02.022","article-title":"Turning cold into hot: Firing up the tumor microenvironment","volume":"6","author":"Duan","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ymthe.2023.08.009_bib68","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.immuni.2020.05.013","article-title":"Structures and mechanisms in the cGAS-STING innate immunity pathway","volume":"53","author":"Zhang","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2023.08.009_bib69","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2111003119","article-title":"STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models","volume":"119","author":"Berger","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2023.08.009_bib70","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ccell.2022.04.009","article-title":"Epigenetic STING silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition","volume":"40","author":"Low","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2023.08.009_bib71","doi-asserted-by":"crossref","DOI":"10.1172\/JCI154229","article-title":"H3.3-G34 mutations impair DNA repair and promote cGAS\/STING-mediated immune responses in pediatric high-grade glioma models","volume":"132","author":"Haase","year":"2022","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2023.08.009_bib72","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41467-022-28523-1","article-title":"T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin-10","volume":"13","author":"Ravi","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2023.08.009_bib73","doi-asserted-by":"crossref","first-page":"6938","DOI":"10.1038\/s41467-021-26940-2","article-title":"Neoadjuvant PD-1 blockade induces T\u00a0cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma","volume":"12","author":"Lee","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2023.08.009_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.105329","article-title":"Cancer cell intrinsic TIM-3 induces glioblastoma progression","volume":"25","author":"Guo","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.ymthe.2023.08.009_bib75","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40425-018-0371-5","article-title":"Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy","volume":"6","author":"Giles","year":"2018","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2023.08.009_bib76","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1158\/1078-0432.CCR-20-2291","article-title":"Concurrent dexamethasone limits the clinical benefit of immune checkpoint blockade in glioblastoma","volume":"27","author":"Iorgulescu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2023.08.009_bib77","first-page":"vdac087","article-title":"The effect of dexamethasone on the microenvironment and efficacy of checkpoint inhibitors in glioblastoma: a systematic review","volume":"4","author":"Swildens","year":"2022","journal-title":"Neurooncol. Adv."},{"key":"10.1016\/j.ymthe.2023.08.009_bib78","article-title":"Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models","volume":"10","author":"Koch","year":"2022","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2023.08.009_bib79","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1200\/JCO.2016.66.6552","article-title":"Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency","volume":"34","author":"Bouffet","year":"2016","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib80","doi-asserted-by":"crossref","DOI":"10.1172\/JCI163447","article-title":"Immune checkpoint blockade in glioblastoma: From tumor heterogeneity to personalized treatment","volume":"133","author":"Arrieta","year":"2023","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2023.08.009_bib81","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/neuonc\/noac099","article-title":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial","volume":"25","author":"Omuro","year":"2023","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib82","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1001\/jamaoncol.2020.3161","article-title":"Effect of vocimagene amiretrorepvec in combination with flucytosine vs standard of care on survival following tumor resection in patients with recurrent high-grade glioma: A randomized clinical trial","volume":"6","author":"Cloughesy","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib83","doi-asserted-by":"crossref","DOI":"10.1172\/JCI151239","article-title":"Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T\u00a0cell response in low-grade gliomas","volume":"132","author":"Ogino","year":"2022","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2023.08.009_bib84","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1158\/1078-0432.CCR-11-0915","article-title":"Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: Implications for clinical trial design","volume":"17","author":"Mineharu","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2023.08.009_bib85","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: The CheckMate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib86","first-page":"180","article-title":"Immune biology of glioma-associated macrophages and microglia: functional and therapeutic implications","volume":"22","author":"Wei","year":"2020","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib87","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/neuonc\/noz185","article-title":"Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages","volume":"22","author":"de Groot","year":"2020","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib88","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41591-019-0694-x","article-title":"Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma","volume":"26","author":"Goswami","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2023.08.009_bib89","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ymthe.2016.10.003","article-title":"Immunosuppressive myeloid cells' blockade in the glioma microenvironment enhances the efficacy of immune-stimulatory gene therapy","volume":"25","author":"Kamran","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2023.08.009_bib90","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ijrobp.2012.12.025","article-title":"Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas","volume":"86","author":"Zeng","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ymthe.2023.08.009_bib91","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/neuonc\/nox208","article-title":"Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143","volume":"20","author":"Omuro","year":"2018","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib92","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/neuonc\/noac055","article-title":"T lymphocytes as dynamic regulators of glioma pathobiology","volume":"24","author":"Cordell","year":"2022","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib93","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1038\/s43018-021-00260-2","article-title":"ERK1\/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma","volume":"2","author":"Arrieta","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ymthe.2023.08.009_bib94","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib95","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: A single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib96","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ymthe.2023.01.006","article-title":"Cancer gene therapy bears fruit","volume":"31","author":"Cripe","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2023.08.009_bib97","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1093\/annonc\/mdv127","article-title":"Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome","volume":"26","author":"Favero","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib98","doi-asserted-by":"crossref","first-page":"283ra54","DOI":"10.1126\/scitranslmed.aaa1408","article-title":"Clonal status of actionable driver events and the timing of mutational processes in cancer evolution","volume":"7","author":"McGranahan","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2023.08.009_bib99","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ccell.2014.12.001","article-title":"Biological and therapeutic impact of intratumor heterogeneity in cancer evolution","volume":"27","author":"McGranahan","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2023.08.009_bib100","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1056\/NEJMoa2202028","article-title":"Oncolytic DNX-2401 virus for pediatric diffuse intrinsic pontine glioma","volume":"386","author":"G\u00e1llego P\u00e9rez-Larraya","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2023.08.009_bib101","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2024947","article-title":"Oncolytic HSV-1 G207 immunovirotherapy for pediatric high-grade gliomas","volume":"384","author":"Friedman","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2023.08.009_bib102","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/s43018-022-00448-0","article-title":"Specific targeting of glioblastoma with an oncolytic virus expressing a cetuximab-CCL5 fusion protein via innate and adaptive immunity","volume":"3","author":"Tian","year":"2022","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ymthe.2023.08.009_bib103","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1371\/journal.pmed.1000010","article-title":"HMGB1 mediates endogenous TLR2 activation and brain tumor regression","volume":"6","author":"Curtin","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.ymthe.2023.08.009_bib104","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.trecan.2022.10.003","article-title":"The emerging field of oncolytic virus-based cancer immunotherapy","volume":"9","author":"Ma","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ymthe.2023.08.009_bib105","doi-asserted-by":"crossref","first-page":"eabh3243","DOI":"10.1126\/sciadv.abh3243","article-title":"G-CSF secreted by mutant IDH1 glioma stem cells abolishes myeloid cell immunosuppression and enhances the efficacy of immunotherapy","volume":"7","author":"Alghamri","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2023.08.009_bib106","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2021.621831","article-title":"Current approaches for glioma gene therapy and virotherapy","volume":"14","author":"Banerjee","year":"2021","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.ymthe.2023.08.009_bib107","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.18632\/oncotarget.27834","article-title":"Immune-stimulatory (TK\/Flt3L) gene therapy opens the door to a promising new treatment strategy against brainstem gliomas","volume":"11","author":"Faisal","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.ymthe.2023.08.009_bib108","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/neuonc\/noy170","article-title":"Viral and other therapies for recurrent glioblastoma: Is a 24-month durable response unusual?","volume":"21","author":"Chiocca","year":"2019","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib109","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S1470-2045(13)70274-2","article-title":"Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): A randomised, open-label, phase 3 trial","volume":"14","author":"Westphal","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib110","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw5680","article-title":"Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial","volume":"11","author":"Chiocca","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2023.08.009_bib111","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/neuonc\/noab271","article-title":"Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial","volume":"24","author":"Chiocca","year":"2022","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2023.01.002","article-title":"Preexisting immunity: Barrier or bridge to effective oncolytic virus therapy?","volume":"70","author":"Groeneveldt","year":"2023","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ymthe.2023.08.009_bib113","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: Replication and immunotherapeutic effects in recurrent malignant glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib114","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1593\/neo.12794","article-title":"Plasmacytoid dendritic cells in the tumor microenvironment: Immune targets for glioma therapeutics","volume":"14","author":"Candolfi","year":"2012","journal-title":"Neoplasia"},{"key":"10.1016\/j.ymthe.2023.08.009_bib115","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.4049\/jimmunol.176.6.3566","article-title":"Fms-like tyrosine kinase 3 ligand recruits plasmacytoid dendritic cells to the brain","volume":"176","author":"Curtin","year":"2006","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib116","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41591-023-02347-y","article-title":"Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: A phase 1\/2 trial","volume":"29","author":"Nassiri","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2023.08.009_bib117","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2219199120","article-title":"Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models","volume":"120","author":"Datta","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2023.08.009_bib118","article-title":"Treatment of adverse radiation effects with Boswellia serrata after failure of pentoxifylline and vitamin E: Illustrative cases","volume":"5","author":"Warnick","year":"2023","journal-title":"J.\u00a0Neurosurg. Case Lessons"},{"key":"10.1016\/j.ymthe.2023.08.009_bib119","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.00453-17","article-title":"Probing dominant negative behavior of glucocorticoid receptor beta through a hybrid structural and biochemical approach","volume":"38","author":"Min","year":"2018","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib120","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1021\/ml500044g","article-title":"Small molecule that reverses dexamethasone resistance in T-cell acute lymphoblastic leukemia (T-ALL)","volume":"5","author":"Cantley","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ymthe.2023.08.009_bib121","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.617937","article-title":"Overcoming glucocorticoid resistance in acute lymphoblastic leukemia: Repurposed drugs can improve the protocol","volume":"11","author":"Olivas-Aguirre","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib122","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/neuonc\/noac024","article-title":"Off-the-shelf, steroid-resistant, IL13Ralpha2-specific CAR T\u00a0cells for treatment of glioblastoma","volume":"24","author":"Brown","year":"2022","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib123","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T\u00a0cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib124","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/jnci\/djy138","article-title":"Olfactory ensheathing cells: A Trojan Horse for glioma gene therapy","volume":"111","author":"Carvalho","year":"2019","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.ymthe.2023.08.009_bib125","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/17425247.2018.1378642","article-title":"Intranasal delivery of stem cell-based therapies for the treatment of brain malignancies","volume":"15","author":"Li","year":"2018","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ymthe.2023.08.009_bib126","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13071525","article-title":"The Flt3L\/Flt3 axis in dendritic cell biology and cancer immunotherapy","volume":"13","author":"Cueto","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2023.08.009_bib127","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.ymthe.2004.08.025","article-title":"Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): Treatment with hsFlt3L inhibits intracranial glioma progression","volume":"10","author":"Ali","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2023.08.009_bib128","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1158\/1078-0432.CCR-13-2140","article-title":"Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models","volume":"20","author":"Candolfi","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2023.08.009_bib129","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/mt.2008.18","article-title":"Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits","volume":"16","author":"King","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2023.08.009_bib130","doi-asserted-by":"crossref","first-page":"6113","DOI":"10.1158\/1078-0432.CCR-09-1087","article-title":"Antiglioma immunological memory in response to conditional cytotoxic\/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression","volume":"15","author":"Ghulam Muhammad","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2023.08.009_bib131","doi-asserted-by":"crossref","first-page":"14443","DOI":"10.1073\/pnas.0913496107","article-title":"Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathology","volume":"107","author":"Larocque","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2023.08.009_bib132","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/mt.2011.77","article-title":"Combined Flt3L\/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen","volume":"19","author":"King","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2023.08.009_bib133","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1593\/neo.11024","article-title":"B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory\/conditionally cytotoxic therapy for glioblastoma","volume":"13","author":"Candolfi","year":"2011","journal-title":"Neoplasia"},{"key":"10.1016\/j.ymthe.2023.08.009_bib134","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/NEN.0000000000000183","article-title":"Increase in both CD14-positive and CD15-positive myeloid-derived suppressor cell subpopulations in the blood of patients with glioma but predominance of CD15-positive myeloid-derived suppressor cells in glioma tissue","volume":"74","author":"Gielen","year":"2015","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib135","first-page":"493","article-title":"Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment","volume":"19","author":"Hardcastle","year":"2017","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib136","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/neuonc\/noaa277","article-title":"Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank","volume":"23","author":"Chuntova","year":"2021","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib137","doi-asserted-by":"crossref","first-page":"vii9","DOI":"10.1093\/neuonc\/nov151","article-title":"Immunosuppressive mechanisms in glioblastoma","volume":"17","author":"Nduom","year":"2015","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib138","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1158\/1078-0432.CCR-18-0047","article-title":"T-cell dysfunction in glioblastoma: Applying a new framework","volume":"24","author":"Woroniecka","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2023.08.009_bib139","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41590-021-00949-7","article-title":"Not-so-opposite ends of the spectrum: CD8(+) T\u00a0cell dysfunction across chronic infection, cancer and autoimmunity","volume":"22","author":"Collier","year":"2021","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib140","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.it.2016.11.005","article-title":"T cell exhaustion in glioblastoma: Intricacies of immune checkpoints","volume":"38","author":"Mirzaei","year":"2017","journal-title":"Trends Immunol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib141","doi-asserted-by":"crossref","first-page":"8509","DOI":"10.1002\/jcp.27782","article-title":"CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: A review","volume":"234","author":"Farhood","year":"2019","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.ymthe.2023.08.009_bib142","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abn9440","article-title":"Immunotherapy of glioblastoma explants induces interferon-gamma responses and spatial immune cell rearrangements in tumor center, but not periphery","volume":"8","author":"Shekarian","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2023.08.009_bib143","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1038\/s41467-022-31340-1","article-title":"Spatiotemporal analysis of glioma heterogeneity reveals COL1A1 as an actionable target to disrupt tumor progression","volume":"13","author":"Comba","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2023.08.009_bib144","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41467-019-13939-z","article-title":"Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T\u00a0cell immunity","volume":"11","author":"Mosaheb","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2023.08.009_bib145","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaq1427","article-title":"IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response","volume":"11","author":"N\u00fa\u00f1ez","year":"2019","journal-title":"Sci. Transl. Med."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001623004410?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001623004410?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T03:46:52Z","timestamp":1778816812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001623004410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":145,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S1525001623004410"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2023.08.009","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined cytotoxic and immune-stimulatory gene therapy using Ad-TK and Ad-Flt3L: Translational developments from rodents to glioma patients","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2023.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s).","name":"copyright","label":"Copyright"}]}}